Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
about
A comparison of robotic arm versus gantry linear accelerator stereotactic body radiation therapy for prostate cancerCurrent role of image-guided robotic radiosurgery (Cyberknife(®) ) for prostate cancer treatmentIs robotic arm stereotactic body radiation therapy “virtual high dose ratebrachytherapy” for prostate cancer? An analysis of comparative effectiveness using published data [corrected].The early result of whole pelvic radiotherapy and stereotactic body radiotherapy boost for high-risk localized prostate cancerUrethrogram-Directed Stereotactic Body Radiation Therapy for Clinically Localized Prostate Cancer in Patients with Contraindications to Magnetic Resonance Imaging.Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer.Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer.Rectal endoscopy findings following stereotactic body radiation therapy for clinically localized prostate cancer.Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study.Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on 3-Year Toxicity.Rectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: systematic review and meta analysis.Stereotactic body radiation therapy for prostate cancer.Evolution of advanced technologies in prostate cancer radiotherapy.Hypofractionation in prostate cancer: radiobiological basis and clinical appliance.The evolution of rectal and urinary toxicity and immune response in prostate cancer patients treated with two three-dimensional conformal radiotherapy techniques.Evolution of hypofractionated accelerated radiotherapy for prostate cancer - the sunnybrook experience.Intensity-Modulated Radiation Therapy with Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: The Georgetown University Experience.ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II.In vivo endorectal dosimetry of prostate tomotherapy using dual MOSkin detectors.Prostate-specific antigen kinetics following hypofractionated stereotactic body radiotherapy boost and whole pelvic radiotherapy for intermediate- and high-risk prostate cancer.Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years.Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer.Six-Dimensional Correction of Intra-Fractional Prostate Motion with CyberKnife Stereotactic Body Radiation Therapy.Real-time in vivo rectal wall dosimetry using MOSkin detectors during linac based stereotactic radiotherapy with rectal displacement.Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer.Real-time intrafraction prostate motion during linac based stereotactic radiotherapy with rectal displacement.Technical note: TROG 15.01 SPARK trial multi-institutional imaging dose measurement.CyberKnife(R) robotic stereotactic radiosurgery and stereotactic body radiation therapy.Stereotactic body-radiotherapy boost dose of 18 Gy vs 21 Gy in combination with androgen-deprivation therapy and whole-pelvic radiotherapy for intermediate- or high-risk prostate cancer: a study protocol for a randomized controlled, pilot trial.
P2860
Q26738278-9A92FF55-5DAF-486C-BDA6-3C48C617BE16Q27009327-4C5BB089-327C-463C-A9DD-42E4DD793E11Q30881854-E5D75C6F-7DDE-4FAD-91F4-55B542AF6BCFQ34433023-F4CD0134-FDB8-4CDF-B17C-2FADE10E0E4CQ36015152-EAC3D6B1-32CB-4464-AE21-E80B45BE9429Q36387814-F1353D09-5ED1-457A-81B2-22FCAFD291B5Q36604355-AB721AB1-88DA-41EF-B411-9996F4B16A7DQ37116581-F90206EE-CA92-402A-A8CF-DA9DEA73C6E0Q37512971-60E57D96-0C56-4D49-86D2-7B40D62921F4Q37627132-A23DBDA6-55FC-4358-A27C-69B62A56F704Q37725623-A4DAAFBD-64B6-4D4C-9C08-805FA11886B6Q37932543-047AB19F-0AF1-4855-8F42-2482469D57CAQ38135708-9AEC097E-B4FB-457E-8972-FB73840FDF81Q38226822-98CBCA58-8E9F-47CA-BDF1-91A560023F51Q38266168-CB3CB1C2-13F6-4DF0-9E54-90DDDABEF28AQ38276603-4D6C1738-CA4D-46ED-957C-D1BA19C54F20Q38839208-894C2993-C7D0-40A8-A805-3EC8F0F5AC15Q39456200-B2A0419C-DDFE-4BBC-9950-3E71FED1CF12Q40807315-6D970D83-7CD4-496A-A545-C6C7F1807DBAQ40858279-345D3060-17C2-4B38-842A-795C12A48010Q41895986-76D5C6A3-0737-4564-B98A-721312F15160Q41985869-B2E9C865-C36B-486C-B61F-7483C0AD3F48Q42175056-813ABE60-D4A9-4EFC-9581-315E9AF0CA2DQ42277882-BC9EADF0-EA87-4CF0-A32E-AF6C839A92CEQ42364887-7834A4EB-5CC6-4EEE-886E-4585E45BD986Q47619701-5FB88D73-17E4-424A-B1D6-878EB189EB5EQ47742446-83932BD6-CEDB-486E-983C-F99721C56B66Q51638589-94FEC320-8CD1-4CC0-9119-8788C0AA53D6Q55261881-38045DFA-CD73-4855-AD71-DF5D69CE4CD6
P2860
Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
@en
Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
@nl
type
label
Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
@en
Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
@nl
prefLabel
Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
@en
Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
@nl
P2093
P2860
P1476
Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
@en
P2093
Alan J Katz
Ferdinand Diblasio
Matthew Witten
Michael Santoro
Richard Ashley
P2860
P304
P356
10.1177/153303461000900605
P577
2010-12-01T00:00:00Z